NeuMoDx Molecular Revenue and Competitors

Detroit, MI USA



Total Funding

Estimated Revenue & Valuation

  • NeuMoDx Molecular's estimated annual revenue is currently $22.1M per year.(i)
  • NeuMoDx Molecular received $20.0M in venture funding in May 2016.
  • 0
  • NeuMoDx Molecular's total funding is $66M.

Employee Data

Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

The NeuMoDxâ?¢ Molecular systems are a family of scalable platforms that fully integrate the entire molecular diagnostic process from â??sample to result.â?? The NeuMoDxâ?¢ 288 and the NeuMoDxâ?¢ 96 Molecular systems are fully automated, continuous random-access analyzers that utilize proprietary NeuDry reagent technology, which integrates magnetic particle affinity capture and real time Polymerase Chain Reaction (PCR) chemistry in a multi-sample microfluidic cartridge. This technology, combined with a platform, uniquely incorporates robotics and microfluidics that result in higher throughput, improved performance, and increased efficiency by eliminating the waste associated with technologies that require reconstitution of lyophilized reagents.\n\nNeuMoDxâ?¢ has recently received FDA 510(k) clearance for its NeuMoDxâ?¢ GBS Assay for the detection of Group B Streptococcus (GBS) DNA in antepartum pregnant women and will continue development of tests to detect and monitor sexually transmitted and infectious diseases. Additionally, NeuMoDxâ?¢ offers a broad range of general purpose reagents and consumables for use by laboratorians in developing qualitative and quantitative Laboratory Developed Tests (LDTs) for use with the NeuMoDxâ?¢ Molecular Systems to detect and amplify DNA and RNA targets.\n\nCall 888-301-6639 or email



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





NeuMoDx Molecular News

2022-04-20 - QIAGEN N.V. (QGEN) CEO Thierry Bernard on Q1 2022 Results - Earnings Call Transcript

Sales trends for QIAstat-Dx and NeuMoDx systems were in line with our full ... well balanced between life science and molecular diagnostics,...

2022-04-17 - Qiagen Q1 Revenues Rise on Strong MDx Sales, Surpassing ...

The firm's molecular diagnostic revenues were up 28 percent year over year to ... and sales for NeuMoDx dropped 15 percent to $27 million,...

2019-09-05 - Global Biochips Market Overview 2019: Market Value ... Lab-on-a-chip and Molecular Biology ... Cancer Therapy; QIAGEN NV Selects NeuMoDx Molecular, Inc for CE-IVD Assays Purchase ...

2019-08-12 - NeuMoDx Files Defense, Counterclaims in BD Patent ...

NEW YORK – NeuMoDx has filed a response with the District of ... by Becton Dickinson that the molecular diagnostics developer infringed on ...

2019-06-20 - BD sues NeuMoDx over patents for diagnostic device

Becton Dickinson (NYSE:BDX) and subsidiaries HandyLab and GeneOhm Sciences Canada have filed a lawsuit against diagnostics company NeuMoDx, claiming patent infringement. BD acquired small diagnostics company HandyLab (Ann Arbor, Mich.) in 2009 for $275 million. HandyLab was developing bench-top ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

NeuMoDx Molecular Funding

DateAmountRoundLead InvestorsReference
2014-04-02$21.0MBPfizer VenturesArticle